EFIL BioScience Inc.

A glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide was approved for the treatment of obesity by the Food and Drug Administration. However, it can cause gastrointestinal events at high doses, limiting its broader use. Combining drugs with multiple mechanisms of action could enhance the weight-reducing effects while minimizing side effects. To this end, we investigated the combined effects of semaglutide and avasimibe, an acyl-CoA:cholesterol acyltransferase 1 (ACAT1) inhibitor, on weight reduction in diet-induced obesity mice. Two cohorts of mice were used: In cohort 1, mice were fed a high-fat (HF) diet for 12 weeks and then randomly assigned to the vehicle, avasimibe [10 mg/kg body weight (BW)], semaglutide (0.4 mg/kg BW), or combination groups. The drugs were administered via subcutaneous (sc) injections on a daily basis. In cohort 2, mice were fed an HF diet for 8 weeks and randomly assigned to the same four groups, but avasimibe was administered at a dose of 20 mg/kg BW, and the drugs were administered every 3 days. In cohort 1, semaglutide initially reduced food intake initially, but this effect was diminished with prolonged administration. Avasimibe, on the other hand, did not affect food intake but prevented weight gain to a lesser extent than semaglutide. Importantly, the combination treatment resulted in the greatest percentage of body weight reduction, along with lower plasma glucose and leptin levels compared to the semaglutide single-treatment group. Cohort 2 confirmed that the superior weight loss in the combination group compared to the other three groups was largely due to a significant reduction in fat mass. Histological analysis of inguinal adipose tissue showed smaller adipocyte size across all treatment groups compared to the vehicle group, with no significant differences among the treatment groups. Collectively, these findings suggest combining semaglutide and avasimibe could be an effective approach to weight management.

Post-harvest processing plays a crucial role in enhancing the bioactive properties of vegetables. This study aimed to investigate the impact of post-harvest aging on parsnip’s bioactive profile and its protective effects against acrolein (Acr)-induced inflammation, a common pollutant and irritant linked to respiratory inflammation.

Parsnips (Pastinaca sativa L.) were aged at 60°C for up to 30 days, with extracts collected at intervals. Total phenolic content (TPC) and antioxidant capacity were assessed using DPPH assays. Key bioactive compounds, including falcarindiol, DDMP, and 5-HMF, were quantified. In vitro studies used BEAS-2B cells to evaluate anti-inflammatory effects, while in vivo tests involved treating Acr-exposed mice with aged parsnip extract to observe cytokine responses.

Aged parsnip extracts showed a 9.96-fold increase in TPC and a 4.25-fold increase in antioxidant capacity after 30 days. Bioactive compounds significantly increased in aged samples, especially falcarindiol and 5-HMF. In vitro, aged parsnip reduced Acr-induced TNF-α and IL-1β expression. In vivo, treated mice showed reduced bronchial inflammation, goblet cell hyperplasia, and cytokine expression compared to controls.

These findings suggest that post-harvest aging enhances parsnip’s antioxidant and anti-inflammatory properties, highlighting its potential as a functional food ingredient for managing inflammation and respiratory health.